Trial Profile
Assessment of Forced Titration to Reach the Effective Dose for Good Glycemic Control in Lantus Treated Type 2 Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Nov 2010
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LANTIT
- Sponsors Sanofi
- 26 Nov 2010 Patient numbers amended from 240 to 241 as reported by ClinicalTrials.gov.
- 03 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2010 Planned end date changed from 1 Jun 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.